More news about ObsEva
Company profiles on startup.ch ObsEva

ObsEva secures $75 million non-dilutive financing

08.08.2019 10:13

Related tags

Pregnancy

ObsEva, focused on the development and commercialization of innovative reproductive health and pregnancy therapies for women, closed a $75 million credit facility with Oxford Finance LLC. Proceeds of the financing are intended for use to advance ObsEva’s late stage development pipeline including Phase 3 trials of nolasiban and of linzagolix.

Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. Proceeds of the financing will be used for Phase 3 trials of nolasiban in patients undergoing embryo transfer (ET) following in vitro fertilization (IVF), and of linzagolix for the treatment of endometriosis-associated pain and heavy menstrual bleeding due to uterine fibroids, as well as initial commercialization expenses for nolasiban. The non-dilutive financing agreement provides ObsEva with up to $75 million borrowing capacity available in three tranches, with the initial $25 million available upon closing.  

“This financing significantly strengthens ObsEva’s financial position by extending our cash runway into the fourth quarter of 2020 as we advance our late stage pipeline toward key clinical and regulatory milestones anticipated later this year,” said Ernest Loumaye, co-founder and CEO of ObsEva.

“Oxford is pleased to be a capital provider for ObsEva to support its pipeline of innovative reproductive health and pregnancy therapies,” said Christopher A. Herr, senior managing director at Oxford. Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $5 billion in loans, with lines of credit ranging from $5 million to $150 million.

(Press release)
Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related News

Related tags

Read more about

More news about ObsEva
Company profiles on startup.ch ObsEva
Please login or
register to use the
bookmark feature

Related News

Related tags

Read more about

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

 

Principal

Entrepreneurs, experts, supporters


On Startupticker, we are regularly publishing background interviews. Find all texts with our “Interview” tag.

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS